BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Poly Medicure Ltd. Share Price

NSE
BSE

NSE : POLYMED

BSE : 531768

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹1,515.10

High

₹1,555.50

Price Summary

Previous Close ₹1,527.80
Day's Range ₹1,515.10 - ₹1,555.50
Open ₹1,520.00
52 Week Range ₹1,182.00 - ₹2,937.60
Volume 1,20,484
Market Cap ₹0.02
Previous Close ₹1,540.25
Day's Range ₹1,516.40 - ₹1,555.00
Open ₹1,538.50
52 Week Range ₹1,184.00 - ₹2,936.70
Volume 4,623
Market Cap ₹0.02

Stocks Summary

Trade Value ( ₹ in Lacs) 1,840.75
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.23
Price/Earning (TTM) 44.05
TTM EPS (₹) 34.30
P/E Ratio 67.10
Book Value(₹) 5.13
PAT Margin (%) 20.19
Face Value (₹) 5.00
ROCE(%) 20.37
Trade Value ( ₹ in Lacs) 71.21
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.23
Price/Earning (TTM) 44.05
TTM EPS (₹) 34.30
P/E Ratio 67.10
Book Value(₹) 5.13
PAT Margin (%) 20.19
Face Value (₹) 5.00
ROCE(%) 20.37

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 4109.37 13757.96
Expenses N/A N/A
PBT 1133.9 3442.69
Operating profit 0.0 0.0
Net profit 851.52 2582.6

Shareholding Pattern

Promoters (% Holding)

62.42%

Mutual funds (% Holding)

8.84%

Non-Institution (% Holding)

16.08%

FI/Banks/Insurance (% Holding)

3.34%

Government (% Holding)

0.00%

FII

5.92%

About Poly Medicure Ltd.

Founded 1995
Managing Director Himanshu Baid
NSE Symbol POLYMED

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,33,847.75 1,824.10 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,72,696.60 6,618.20 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,41,859.41 4,252.05 3,101.60 - 3,101.60
Dr. Reddy's Laboratories Ltd. 1,10,420.94 1,287.95 1,129.40 - 1,129.40
Apollo Hospitals Enterprise Ltd. 1,09,839.98 7,727.50 6,677.50 - 6,677.50
Cipla Ltd. 1,05,811.45 1,334.85 1,165.70 - 1,165.70
Lupin Ltd. 1,05,320.35 2,350.00 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 96,662.57 1,011.45 903.00 - 903.00
Mankind Pharma Ltd. 92,743.95 2,266.80 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 89,720.85 901.65 835.50 - 835.50
no-content No Records Found

Latest News

Alt Text
Equity

Asian Warehousing informs about updates

Alt Text
Ipo

Recode Studios coming with IPO to raise up to Rs 44.59 crore

Alt Text
Finance

Currency futures for May expiry trade tad weaker with 1.07% decrease in OI

Alt Text
Economy

Govt reports 8.7% growth in GST collection for April

View All
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image

Article Listing News

Feb
13
2026
EQUITY Posted on Feb 13th 2026

Poly Medicure informs about statement of deviation or variation

Poly Medicure has informed that the Company had raised funds by way of allotment of 53,19,148 (Fifty Three Lakh Nineteen Thousand One Hundred Forty Eight) equity shares of face value of Rs 5 each, to qualified institutional buyers (QIBs), at a price of Rs 1880 per Equity Share (including premium of Rs 1875 per Equity Share), pursuant to the resolution passed by the Board of Directors dated 29th June, 2024, special resolution passed by the Shareholders through postal ballot on 5th August, 2024, the preliminary placement document dated 19th August, 2024, the placement document dated 22nd August, 2024 and resolution of the QIP Committee of the Board of Directors dated 22nd August, 2024 (the Issue). The Audit Committee, at its meeting held on February 05, 2026, has reviewed the actual utilization of funds received for an amount aggregating ~Rs 99,999.98 lakh, pursuant to the Issue. In this connection, it submitted that there is no deviation or variation from the objects of the Issue, in the utilization of proceeds, as stated in the placement document, during the quarter ended December 31, 2025. In terms of Regulations 32(1), 32(2) and 32(3) of the SEBI Listing Regulations, a statement of deviation or variation, if any, in utilization of funds raised through Qualified Institutions Placement (QIP), for the quarter ended December 31, 2025, duly reviewed by the Audit Committee, in the prescribed format is also enclosed.
The above information is a part of company’s filings submitted to BSE.
Read More
May
4
2026
EQUITY Posted on May 4th 2026

Venus Remedies informs about updates

Venus Remedies has informed that the links of the posts made on the official social media handles (lnstagram, Facebook, Linkedln, and X) of the Company regarding Notice to Shareholders about opening of Special Vvindow for Re-lodgement of transfer requests of Physical Shares in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30.01.2026 are given as below: https://www.facebook.com/share/p/lHDBagpo22/ http://www.instagrm.com/p/DX53h_iAFCXIAitm_souwig_web_copy_link&igshEMZRIODBi NWFIZA=
https://www.Iinkedin.com/feed/update/urn:li:activity:7456930643420041216 https://x.com/remediesvenus/status/2051166080782270877?s=20
The above information is a part of company’s filings submitted to BSE.
Read More
May
4
2026
EQUITY Posted on May 4th 2026

GKB Ophthalmics informs about board meeting

Pursuant to Regulation 29 read with Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, GKB Ophthalmics has informed that a Meeting of the Board of Directors of the Company will be held on Wednesday, May 27, 2026 at the Registered Office of the Company, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026. The Notice can be accessed at the Company's website at www.gkb.net. Further, with reference to the above meeting of the Board of Directors that the Trading Window for dealing with equity shares of the Company, by designated persons, under the SEBI (Prohibition of Insider Trading) Regulations, 2015, had been closed from April 01, 2026, will now re-open after the completion of 48 hours from the date of submission of financial results to the Stock Exchange. This communication has been sent to all the Directors and all the designated employees of the Company.

The above information is a part of company’s filings submitted to BSE.

Read More
May
4
2026
EQUITY Posted on May 4th 2026

Sudarshan Pharma Industries informs about newspaper advertisement

Sudarshan Pharma Industries has informed that it enclosed the newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March 2026, published in the newspapers: Mumbai Lakshdeep and Financial Express.
The above information is a part of company’s filings submitted to BSE.
Read More
May
4
2026
EQUITY Posted on May 4th 2026

OneSource Specialty Pharma informs about press release

OneSource Specialty Pharma has informed that it enclosed Press Release issued by the Company titled: OneSource Supports Second Generic Semaglutide Approval in Canada Enables commercialisation for the first two entrants in the world’s second-largest semaglutide market.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Poly Medicure Ltd. ?

The current share price of Poly Medicure Ltd. is ₹1,527.80 as of 2026-05-04.

The market capitalisation of Poly Medicure Ltd. is ₹15,315.93 as of 2026-04-30.

The 1-year return of Poly Medicure Ltd. is 15.70% as of 2026-05-04.

The P/E ratio of Poly Medicure Ltd. is 67.10 as of 2026-05-04.

The 52-week high and low of Poly Medicure Ltd. are ₹2,937.60 and ₹1,182.00, respectively, as of 2026-05-04.

The dividend yield of Poly Medicure Ltd. is 0.2316% as of2026-04-30.

You can buy Poly Medicure Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Poly Medicure Ltd. is Himanshu Baid.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Personal Loan
My Accounts
My Accounts
Explore
Explore